Articles by Melissa Badamo
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
William Morice, MD, PhD, President and CEO of Mayo Clinic Laboratories, discussed a collaboration to expand cancer testing.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
This issue includes a feature on government funding, an editor's letter by Mehdi H. Hamadani, MD, and more.
Dr. Parekh discussed the promising future of trispecifics, the group of patients with the largest unmet need, and more.
Gaurav Goyal, MD, spoke to Blood Cancers Today about strategies and guidelines for incorporating PROs into clinical trials.
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
Douglas Graham, MD, PhD, a hematologist-oncologist specializing in pediatric leukemia, was recognized in Atlanta Magazine.
Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
Andrew M. Evens, DO, MBA, MSc, shared practice-changing studies in Hodgkin lymphoma and what to expect in 2025.
Martin Dreyling, MD, discusses the TRIANGLE study and the shifting roles of autologous HSCT and chemotherapy in MCL.
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.